We have read with interest the abstract presented at the last ECCO Congress by Tenjarla & Abinusawa 1 . While we agree with the authors' final statement that 'consideration of the potential release profiles [of 5-ASA] may be a useful tool in choosing the most appropriate treatment', we question the findings on Salofalk granules, i.e., that Salofalk 1.5 g granules release only approximately 20% of its total amount of 5-aminosalicylic acid in different dissolution experiments.
In contrast to the conclusions on the poster of Tenjarla & Abinusawa that 'Salofalk granules may fail to release the majority of their 5-ASA load at colonic pH values', several studies published as full articles in established journals have shown the favourable release profile of Salofalk granules.
2, 3 To further elucidate these contradicting data, replication of the dissolution experiments was initiated. Strictly following the methods as used by Tenjarla & Abinusawa, 1 we found an invitro release of 5-ASA of more than 90% after 4 h in Experiment A and after 7 h in Experiment B (see Figs. 1 and 2), which is in line with earlier published data on Salofalk granules, 3 but in strong contradiction to Tenjarla & Abinusawa.
The in-vitro release profiles of Mezavant 1200 mg under both experimental designs as described by Tenjarla & Abinusawa could be confirmed (see Figs. 1 and 2) .
Salofalk granules have not only been shown to exert a favourable release profile for 5-ASA, 2,3 but a number of well designed, randomised, double-blind, controlled pivotal phase III studies clearly demonstrate significant therapeutically efficacy both for active ulcerative colitis, [4] [5] [6] [7] and for maintenance of remission in ulcerative colitis. 8 Moreover, recently a pooled analysis of several clinical studies has demonstrated a very high efficacy of Salofalk granules in active UC confined to the distal part of the colon, which again points to a sufficient release of 5-ASA from Salofalk granules, 9 and thus confirms the suitability of this formulation to target colonic inflammation. 
